477 related articles for article (PubMed ID: 26915027)
21. Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers.
Kim CJ; Rousseau R; Huibner S; Kovacs C; Benko E; Shahabi K; Kandel G; Ostrowski M; Kaul R
AIDS; 2017 Jul; 31(11):1529-1534. PubMed ID: 28463882
[TBL] [Abstract][Full Text] [Related]
22. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
Gupta SB; Pujari SN; Joshi SR; Patel AK;
J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
[TBL] [Abstract][Full Text] [Related]
23. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study.
Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S;
PLoS One; 2015; 10(10):e0139981. PubMed ID: 26465293
[TBL] [Abstract][Full Text] [Related]
24. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].
;
Enferm Infecc Microbiol Clin; 2007 Jan; 25(1):32-53. PubMed ID: 17261244
[TBL] [Abstract][Full Text] [Related]
25. Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
Spritzler J; Mildvan D; Russo A; Asthana D; Livnat D; Schock B; Kagan J; Landay A; Haas DW;
Clin Infect Dis; 2003 Aug; 37(4):551-8. PubMed ID: 12905140
[TBL] [Abstract][Full Text] [Related]
26. Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.
Stefic K; Novelli S; Mahjoub N; Seng R; Molina JM; Cheneau C; Barin F; Chaix ML; Meyer L; Delaugerre C;
J Infect Dis; 2018 May; 217(11):1793-1797. PubMed ID: 29509924
[TBL] [Abstract][Full Text] [Related]
27. [New therapeutic strategies in HIV infection-immune reconstitution and virus suppression].
Herzmann C; Düesberg U; Arastéh K
Med Klin (Munich); 2004 Jun; 99(6):323-5. PubMed ID: 15221057
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question.
Eholié SP; Badje A; Kouame GM; N'takpe JB; Moh R; Danel C; Anglaret X
AIDS Res Ther; 2016; 13():27. PubMed ID: 27462361
[TBL] [Abstract][Full Text] [Related]
29. Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.
Kaplan-Lewis E; Aberg JA; Lee M
Curr HIV/AIDS Rep; 2016 Oct; 13(5):297-308. PubMed ID: 27562769
[TBL] [Abstract][Full Text] [Related]
30. Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapy.
Butler SL; Valdez H; Westby M; Perros M; June CH; Jacobson JM; Levy Y; Cooper DA; Douek D; Lederman MM; Tebas P
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):297-303. PubMed ID: 21792065
[TBL] [Abstract][Full Text] [Related]
31. Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.
Kim CJ; Walmsley SL; Raboud JM; Kovacs C; Coburn B; Rousseau R; Reinhard R; Rosenes R; Kaul R
HIV Clin Trials; 2016 Jul; 17(4):147-57. PubMed ID: 27267710
[TBL] [Abstract][Full Text] [Related]
32. Contribution of Adipose Tissue to the Chronic Immune Activation and Inflammation Associated With HIV Infection and Its Treatment.
Bourgeois C; Gorwood J; Olivo A; Le Pelletier L; Capeau J; Lambotte O; Béréziat V; Lagathu C
Front Immunol; 2021; 12():670566. PubMed ID: 34220817
[TBL] [Abstract][Full Text] [Related]
33. Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research.
Muccini C; Crowell TA; Kroon E; Sacdalan C; Ramautarsing R; Seekaew P; Phanuphak P; Ananworanich J; Colby DJ; Phanuphak N
AIDS Res Ther; 2019 Sep; 16(1):25. PubMed ID: 31492161
[TBL] [Abstract][Full Text] [Related]
34. Immune restoration and CD4+ T-cell function with antiretroviral therapies.
Lederman MM
AIDS; 2001 Feb; 15 Suppl 2():S11-5. PubMed ID: 11424971
[TBL] [Abstract][Full Text] [Related]
35. Modeling aging in HIV infection in nonhuman primates to address an emerging challenge of the post-ART era.
He T; Falwell E; Brocca-Cofano E; Pandrea I
Curr Opin Virol; 2017 Aug; 25():66-75. PubMed ID: 28803049
[TBL] [Abstract][Full Text] [Related]
36. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.
Lichtfuss GF; Cheng WJ; Farsakoglu Y; Paukovics G; Rajasuriar R; Velayudham P; Kramski M; Hearps AC; Cameron PU; Lewin SR; Crowe SM; Jaworowski A
J Immunol; 2012 Aug; 189(3):1491-9. PubMed ID: 22745371
[TBL] [Abstract][Full Text] [Related]
37. Early immune senescence in HIV disease.
Desai S; Landay A
Curr HIV/AIDS Rep; 2010 Feb; 7(1):4-10. PubMed ID: 20425052
[TBL] [Abstract][Full Text] [Related]
38. Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.
Younas M; Psomas C; Reynes J; Corbeau P
HIV Med; 2016 Feb; 17(2):89-105. PubMed ID: 26452565
[TBL] [Abstract][Full Text] [Related]
39. The road to success. Long-term prognosis for persons living with HIV in Denmark - time trends and risk factors.
Lohse N
Dan Med J; 2016 Feb; 63(2):. PubMed ID: 26836803
[TBL] [Abstract][Full Text] [Related]
40. Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective.
Thorner A; Rosenberg E
Drugs; 2003; 63(13):1325-37. PubMed ID: 12825959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
